Results 101 to 110 of about 57,995 (263)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

Journal of Clinical Endocrinology and Metabolism, 2014
Context: Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many patients do not achieve biochemical control ...
A. Colao, M. Bronstein, P. Freda, F. Gu, C. Shen, C. Shen, M. Gadelha, M. Fleseriu, A. V. D. Lely, A. Farrall, K. H. Reséndiz, Matthieu Ruffin, Yinmiao Chen, M. Sheppard   +13 more
semanticscholar   +1 more source

Systematic review and meta‐analysis of the efficacy and safety of [177Lu]Lu‐edotreotide ([177Lu]Lu‐DOTATOC) for the treatment of neuroendocrine tumors

Journal of Neuroendocrinology, EarlyView.
Abstract [177Lu]Lu‐edotreotide is a radiopharmaceutical therapy (RPT) targeting somatostatin receptors, which are commonly overexpressed on neuroendocrine tumors (NETs). This systematic literature review and meta‐analysis describes the efficacy and safety of [177Lu]Lu‐edotreotide in patients with NETs.
Richard P. Baum, Julia G. Fricke, Tristan Ruhwedel, Holger Amthauer, Erika Patricia Azorin‐Vega, Dieter Hörsch, Riccardo Laudicella, Vikalp Maheshwari, Martin A. Walter, Berna Degirmenci Polack, Simon F. Spiegl, Guillaume P. Nicolas   +11 more
wiley   +1 more source

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing’s Syndrome

Case Reports in Endocrinology, 2016
A 30-year-old Caucasian man presented with severe Cushing’s syndrome (CS) resulting from ectopic adrenocorticotropin syndrome (EAS) from a metastatic pancreatic neuroendocrine tumor.
Andreas G. Moraitis, Richard J. Auchus
doaj   +1 more source

Focal Spot, Fall/Winter 1993 [PDF]

, 1993
https://digitalcommons.wustl.edu/focal_spot_archives/1065/thumbnail ...

core   +1 more source

Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors [PDF]

, 2015
Over the past few years, knowledge regarding the molecular pathology of sporadic pancreatic neuroendocrine tumors (PNETs) has increased substantially, and a number of targeted agents have been tested in clinical trials in this tumor type.
Ahn, Balogh, Bergers, Berruti, Capurso, Capurso, Carew, Castellano, Chamberlain, Chan, Chan, Chen, Clynes, Corbo, Corbo, Couvelard, De Wilde, Di Florio, Di Florio, Di Florio, Fazio, Fendrich, Gaur, Gurung, Han, Heaphy, Heaphy, Hobday, Hopfner, House, Jacinto, Jensen, Jiao, Karnik, Karnik, Komori, Kulke, Laplante, Loewith, Lovejoy, Luzi, Marinoni, Marion-Audibert, Mendel, Meric-Bernstam, Missiaglia, Mocellin, Panzuto, Papouchado, Passacantilli, Perren, Pàez-Ribes, Raymond, Sarbassov, Scoazec, Shah, Shi, Tang, Vinagre, Wang, Yang, Yao, Yuan, Zhang, Zhang   +64 more
core   +1 more source

Erythematous Papules and Plaques in an Infant Receiving Glucagon Therapy

JEADV Clinical Practice, EarlyView.
Sara Al Janahi, Alya Al‐Ali, Meera Al Adawi, Yusra S. Al Ali, Harish Bangalore   +4 more
wiley   +1 more source

Management Strategies for Refractory Esophageal Varices

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Refractory esophageal varices that are difficult to control or unresponsive to endoscopic treatment remain a major clinical challenge in the management of portal hypertension. This review provides a comprehensive overview of treatment strategies for these cases, along with a comparative analysis of the American Association for the Study of ...
Keita Maki, Hiroaki Haga, Yoshiyuki Ueno
wiley   +1 more source

Time spent with cats is never wasted: Lessons learned from feline acromegalic cardiomyopathy, a naturally occurring animal model of the human disease [PDF]

, 2018
BackgroundIn humans, acromegaly due to a pituitary somatotrophic adenoma is a recognized cause of increased left ventricular (LV) mass. Acromegalic cardiomyopathy is incompletely understood, and represents a major cause of morbidity and mortality.
A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Mestron, A Piovesan, AC Dirtu, AM Pereira, B Posch, BJ Maron, BPP Meij, BR Bond, C Paige, C-Y Liu, CJL Little, CR Lamb, David B. Church, David J. Connolly, DJ Connolly, F Fracassi, G Jacobs, G Lombardi, G Lombardi, J Dal, J Gilbert, JA Myers, JK Sangster, JM Fletcher, JR Payne, JT Lie, Kieran Borgeat, LJ Wilkie, Lois Wilkie, M Galderisi, M Lesser, M Maxie Grant, M Nishiki, M Rosca, M-LL Jaffrain-Rea, MD Kittleson, ME Peterson, ME Peterson, NJ Pereira, Norelene Harrington, NS Moise, NS Moise, O Kershaw, OM Dekkers, P Menaut, PR Fox, PR Fox, PR Fox, PR Fox, PR Fox, R Baldelli, R Gostelow, R Pivonello, RC Weichselbaum, S Brown, S Fazio, S Fazio, S Fazio, S Fieffe, S Murarka, S Niessen, SJM Niessen, SJM Niessen, SJM Niessen, SK Liu, SK Liu, Stijn J. M. Niessen, SV Keyte, T Wagner, T. Rosol, Vincenzo Lionetti, Virginia Luis Fuentes, WL McGuffin   +80 more
core   +2 more sources

Terlipressin for Hepatorenal Syndrome in Patients With Early‐Stage Acute‐on‐Chronic Liver Failure

Liver International, Volume 45, Issue 12, December 2025.
ABSTRACT Background & Aims Hepatorenal syndrome‐acute kidney injury (HRS‐AKI) is a life‐threatening complication of decompensated cirrhosis. The US Food and Drug Administration approved terlipressin use for HRS‐AKI based on the CONFIRM study, which demonstrated a significant improvement in HRS reversal with terlipressin versus placebo.
Don C. Rockey, Fredric Gordon, Paul J. Thuluvath, David Victor, Nyingi Kemmer, Sanaz Cardoza, Khurram Jamil, R. Todd Frederick   +7 more
wiley   +1 more source

Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers

British Journal of Clinical Pharmacology, 2015
Aims The aim was to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of octreotide subcutaneous (s.c.) depot, a novel octreotide formulation. Methods This was a phase I, randomized, open label study.
F. Tiberg, John Roberts, C. Cervin, M. Johnsson, S. Sarp, A. Tripathi, Margareta Linden   +6 more
semanticscholar   +1 more source